Literature DB >> 8666346

Hepatic mucosal mast cell hyperplasia in rats with secondary biliary cirrhosis.

K P Rioux1, K A Sharkey, J L Wallace, M G Swain.   

Abstract

Mast cells have been shown to play a role in many chronic inflammatory and fibrotic disorders. However, their possible contribution to the pathological changes that occur in liver cirrhosis is unknown. To explore this, we examined whether changes in hepatic mast cell number and mediator content were associated with fibrotic changes in experimental biliary cirrhosis. Rats were studied 7, 14, or 21 days after bile duct resection (BDR). Hepatic mast cells were identified by histochemical and immunohistochemical stains. Rat mast cell protease II (RMCP-II), a marker of mast cell degranulation, was measured in liver by enzyme-linked immunosorbent assay. Hepatic collagen deposition was assessed by Sirius Red F3BA staining. In day 21 BDR rats, there was a one- to twofold increase (P < .001) in the number of hepatic mast cells, but this was not observed in day 7 or 14 BDR rats. Mild fibrotic changes were noted in BDR rat livers as early as 7 days after induction of cholestasis. Significant expansion and organization of fibrous tissue had occurred in day 14 BDR rats which progressed to bridging fibrosis by day 21. Liver RMCP-II levels were decreased by 50 percent (P < .05) and mast cell degranulation was apparent as shown by histamine immunostaining. These results suggest that hepatic mast cell hyperplasia and degranulation occur during prolonged cholestasis in the rat. Although these changes do not correlate with the onset of hepatic fibrosis, they do occur at a time during which there is significant deposition and organization extracellular matrix elements. Hepatic mast cells, by releasing profibrogenic mediators, may contribute to fibrotic changes in biliary cirrhosis.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8666346     DOI: 10.1002/hep.510230433

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  10 in total

1.  Portacaval shunting attenuates portal hypertension and systemic hypotension in rat anaphylactic shock.

Authors:  Chiaki Kamikado; Toshishige Shibamoto; Wei Zhang; Yuhichi Kuda; Chieko Ohmukai; Yasutaka Kurata
Journal:  J Physiol Sci       Date:  2010-12-22       Impact factor: 2.781

2.  Immunological similarities between primary sclerosing cholangitis and chronic sclerosing sialadenitis: report of the overlapping of these two autoimmune diseases.

Authors:  K Tsuneyama; K Saito; B H Ruebner; I Konishi; Y Nakanuma; M E Gershwin
Journal:  Dig Dis Sci       Date:  2000-02       Impact factor: 3.199

Review 3.  Microanatomy of the liver immune system.

Authors:  Eszter Nemeth; Alan W Baird; Cliona O'Farrelly
Journal:  Semin Immunopathol       Date:  2009-07-29       Impact factor: 9.623

Review 4.  Pathogenesis and treatment of pruritus in cholestasis.

Authors:  Andreas E Kremer; Ulrich Beuers; Ronald P J Oude-Elferink; Thomas Pusl
Journal:  Drugs       Date:  2008       Impact factor: 9.546

5.  Effect of neonatal capsaicin treatment on haemodynamics and renal function in cirrhotic rats.

Authors:  Y Li; D Song; Y Zhang; S S Lee
Journal:  Gut       Date:  2003-02       Impact factor: 23.059

Review 6.  The complex functions of mast cells in chronic human liver diseases.

Authors:  Barbara Franceschini; Giorgia Ceva-Grimaldi; Carlo Russo; Nicola Dioguardi; Fabio Grizzi
Journal:  Dig Dis Sci       Date:  2006-11-11       Impact factor: 3.487

7.  Immunohistochemical localization and mRNA detection of Rab3D and/or Rab3B in rat von Ebner's glands, parotid gland, pancreas, and liver.

Authors:  R B Field; D H Kruse; R S Redman
Journal:  Histochem J       Date:  2001-02

Review 8.  Mast Cells in Liver Fibrogenesis.

Authors:  Ralf Weiskirchen; Steffen K Meurer; Christian Liedtke; Michael Huber
Journal:  Cells       Date:  2019-11-13       Impact factor: 6.600

9.  Experimental obstructive cholestasis: the wound-like inflammatory liver response.

Authors:  María-Angeles Aller; Jorge-Luis Arias; Jose García-Domínguez; Jose-Ignacio Arias; Manuel Durán; Jaime Arias
Journal:  Fibrogenesis Tissue Repair       Date:  2008-11-03

10.  Efficacy of a Peruvian Botanical Remedy (Sabell A4+) for Treating Liver Disease and Protecting Gastric Mucosal Integrity.

Authors:  Mark G Swain; John L Wallace; D Lorne Tyrrell; José Cabanillas; Steven K H Aung; Hongqun Liu; Lindsay Finnie-Carvalho; Grishma Shrestha; Hugh A Semple; Francis H Y Green
Journal:  Evid Based Complement Alternat Med       Date:  2019-10-24       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.